Molecular Targeting To Telomerase And Cancer Cell Immortality By A Novel Inhibitor
Funder
National Health and Medical Research Council
Funding Amount
$430,812.00
Summary
Infinite growth of cancer cells is a hallmark of cancer. Telomerase is required for cancer cell immortality. Inhibition of telomerase may thus offer an opportunity to stop cancer cells. We have identified an inhibitor of telomerase. This project will study the mechanisms of action of the novel inhibitor, investigating how to control cancer cell immortality as a baseline for more applied anti-cancer therapeutic studies.
Targeting Adaptive Mechanisms To Endoplasmic Reticulum Stress In Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$511,294.00
Summary
Melanoma is a major Australian health problem, but there is no curative treatment once the disease spreads beyond the skin. We will study the role the response of melanoma cells to stress conditions of an organelle called endoplasmic reticulum in determining sensitivity of melanoma to killing induced by therapeutic drugs. If successful, this study will provide much needed new insights into the resistance of melanoma to treatment and point to new treatment approaches against the disease.
Downregulation Of N-myc Oncogene Expression As A Therapeutic Strategy For Childhood Neuroblastoma.
Funder
National Health and Medical Research Council
Funding Amount
$145,990.00
Summary
Neuroblastoma is a common cancer of young children which, despite the use of powerful anticancer drugs that cure other childhood cancers, has only a 40% survival rate. Many laboratories have shown that the most aggressive neuroblastoma tumours, which are most resistant to the action of anticancer drugs, have an abnormal number of copies of a cancer-associated gene, called N-myc. Patients whose tumours have multiple N-myc copies have dismal survival prospects, and new treatments for such patients ....Neuroblastoma is a common cancer of young children which, despite the use of powerful anticancer drugs that cure other childhood cancers, has only a 40% survival rate. Many laboratories have shown that the most aggressive neuroblastoma tumours, which are most resistant to the action of anticancer drugs, have an abnormal number of copies of a cancer-associated gene, called N-myc. Patients whose tumours have multiple N-myc copies have dismal survival prospects, and new treatments for such patients are urgently needed. Several studies, using models of neuroblastoma cells growing in the laboratory, have shown that it is possible to create small fragments of genetic material which can specifically switch off the N-myc gene. When this happens, the neuroblastoma cells behave in a less aggressive and malignant way. We have recently shown that these genetic fragments are capable of reducing the growth of tumours in mice which have been genetically manipulated to develop neuroblastoma. We now want to develop new types of genetic fragments (DNAzymes) that will be even more effective at switching off N-myc and inhibiting neuroblastoma development, because these fragments may be extremely valuable for treating neuroblastoma in patients.Read moreRead less
Characterisation Of The Molecular Pathogenesis Of Cancer Cachexia Syndrome In Colorectal Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$100,381.00
Summary
Cachexia is a hypermetabolic wasting syndrome involving depletion of both fat and muscle which affects 80% of cancer patients. The exact mechanisms of this syndrome are unknown at the molecular level and this affects our ability to predict, prevent or treat this problem. This study aims to elucidate the molecular mechanisms of cancer cachexia syndrome with a view to implementing nutritional, exercise and pharmacological interventions to prevent its onset.
Structural and pharmaceutical studies on a novel human protein, MIC-1. Cancer and obesity are two of the main health problems facing Australia, as reflected by the National Research Priority: Promoting and Maintaining Good Health. This project will develop new diagnostic tools for early cancer detection and prognosis using the protein, MIC-1. MIC-1 is responsible for cachexia, a wasting disorder responsible for 25% of cancer deaths, which has no effective therapy. MIC-1 and antibodies neutrali ....Structural and pharmaceutical studies on a novel human protein, MIC-1. Cancer and obesity are two of the main health problems facing Australia, as reflected by the National Research Priority: Promoting and Maintaining Good Health. This project will develop new diagnostic tools for early cancer detection and prognosis using the protein, MIC-1. MIC-1 is responsible for cachexia, a wasting disorder responsible for 25% of cancer deaths, which has no effective therapy. MIC-1 and antibodies neutralising MIC-1 may provide therapeutic agents to control cancer cachexia and severe obesity. The project will optimise these molecules for therapeutic uses. These diagnostic and therapeutic tools will form the basis of a spin-off company for commercialisation. Read moreRead less
Biomarkers Of Phenotype, Prognosis And Response To Therapy In Pancreatic Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$105,845.00
Summary
Pancreatic cancer (PC) is the 4th leading cause of cancer deaths in our society. This research is aimed at the discovery of novel biomarkers with the ability to forecast prognosis and response to treatments in patients with PC. Ultimately, this will lead to the “individualisation” of the treatment for each patient, so that the most appropriate therapy could be given to an individual patient. This would significantly improve the overall survival and the quality of life for patients.
Radiolabelled MMP binding agents for the identification, quantification, and targeting of MMPs in central nervous system (CNS) disorders and tumours. Cancer and diseases of the central nervous system (CNS) represent two of the major health challenges facing Australia because of the aging population. In order to address these challenges we need to develop methods for identifying tumours and CNS diseases using non-invasive technologies and at an early stage so that treatments can be applied when t ....Radiolabelled MMP binding agents for the identification, quantification, and targeting of MMPs in central nervous system (CNS) disorders and tumours. Cancer and diseases of the central nervous system (CNS) represent two of the major health challenges facing Australia because of the aging population. In order to address these challenges we need to develop methods for identifying tumours and CNS diseases using non-invasive technologies and at an early stage so that treatments can be applied when they are most likely to work. In this project, we are developing new radiolabelled compounds that will enable the imaging of tumours, tumour metastases and CNS diseases states.Read moreRead less